Study confirms recommendations for genetic screening in patients with triple-negative breast cancer

the ONA take:

The value of genetic testing and which patients would benefit from the knowledge gained is an often-researched question. Results of recent research from Mayo Clinic Cancer Center suggest that most patient with triple-negative breast cancer should undergo genetic testing for mutations in known breast cancer predisposition genes, including BRCA1 and BRCA2. In addition, these results further support the National Comprehensive Cancer Network (NCCN) guidelines for genetic testing of this patient group. The Mayo Clinic researchers assessed the frequency of mutations in predisposition genes in 1,824 cases of triple-negative breast cancer seen at 12 oncology clinics in the United States and Europe, as part of the Triple-Negative Breast Cancer Consortium. Almost 15% of patients with triple-negative breast cancer had harmful mutations in predisposition genes, with 11% having mutations in the BRCA1 and BRCA2 genes. The remaining patients had mutations in 15 other predisposition genes, including DNA repair genes PALB2, BARD1, and RAD51C.

 

Triple-negative breast cancer, a very aggressive form of the disease, is difficult to treat because these tumors are lacking estrogen, progesterone, and HER-2 receptors, which are targeted by the most common and most effective treatments. Recent studies, however, suggest these patients may harbor genetic mutations that make them more likely to respond to other treatments, such as chemotherapy or PARP inhibitors. NCCN guidelines recommend screening when there is a family history of cancer or the patient is younger than 60 years at diagnosis. Following these guidelines, only 1% of patients carrying mutations were missed. The researchers conclude that their results provide evidence to support the NCCN guideline recommendations for genetic testing in patients with triple-negative breast cancer.

Study confirms recommendations for genetic screening in patients with triple-negative breast cancer
Study confirms recommendations for genetic screening in patients with triple-negative breast cancer
- Most patients with triple-negative breast cancer should undergo genetic testing for mutations in known breast cancer predisposition genes, including BRCA1 and BRCA2, a Mayo Clinic-led study has found. The findings come from the largest analysis to date of genetic mutations in this aggressive form of breast cancer.
READ FULL ARTICLE From Mayoclinic
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs